BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. BSGI serves as a complementary diagnostic adjunct procedure to mammography and ultrasound for difficult-to-diagnose patients. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image.

Solis has been using the Dilon 6800 in its Solis-Bertrand Breast Center in Greensboro, NC, for over a year. Molecular imaging will be used as a part of Solis' advanced imaging program for breast diagnosis, which also includes the use of breast MRI, when appropriate.

"BSGI has proven to be an important adjunct to mammography and ultrasound in the diagnosis of breast cancer at the Solis-Bertrand Center, and we are excited to be the first in the Metroplex to offer this important advance in care," said Brad Hummel, CEO of Solis.

"At Solis our commitment is to the women of our communities, and this commitment extends to selecting technologies that demonstrate diagnostic value in our mission to diagnose cancers when they are small and at their most treatable. We studied the BSGI extensively at our center in Greensboro, and determined that it offered benefits that we needed to bring to the Metroplex," said Hummel.

Bob Moussa, CEO of Dilon Technologies added, "We are delighted to have an institution as prestigious as Solis Women's Health include our advanced technology as part of their diagnostic offering. It speaks volumes for their commitment to enhancing the standard of health care in the communities in which they operate. By working closely together, Solis and Dilon will continue to help the fight against cancer."

 Source: Dilon Technologies Inc.